Navigation Links
BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment
Date:1/13/2014

JERUSALEM, Jan. 13, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has filed the necessary regulatory submissions to commence a Phase 1 trial for BL-8040, a novel treatment for the mobilization of stem cells from the bone marrow to the peripheral blood circulation. The regulatory submissions were filed with the Hadassah Medical Center Institutional Review Board (IRB), and the study is expected to commence during the second quarter of 2014.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

The Phase 1 study will be divided into two parts. Part 1 is a randomized, double-blind, placebo-controlled dose escalation study exploring the safety and tolerability of escalating repeated doses of BL-8040 in healthy volunteers. Secondary objectives include assessment of the efficacy of BL-8040 in mobilizing stem cells as a stand-alone therapy, as well as monitoring the pharmacokinetic profile of the drug. This part will be performed in up to 4 cohorts, with 8 healthy volunteers in each cohort. Part 1 of the study will serve to select the optimal safe and efficacious dose of BL-8040 to be used as a stand-alone therapy in Part 2 of the study.

Part 2 is an open-label study designed to assess BL-8040's stem cell mobilization capacity, as well as the yield of cells collected by leukapheresis. Secondary endpoints of the study include evaluation of the viability and biological activity of cells mobilized by BL-8040 and collected by leukapheresis. This part will be performed in a single cohort of 8 healthy volunteers who will receive the selected dose regimen of BL-8040 based on the data from Part 1.

"Increas
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment
2. BioLineRx to Present at Biotech Showcase Conference in San Francisco
3. BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
4. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
5. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
6. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
7. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
8. BioLineRx Reports Third Quarter 2013 Financial Results
9. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
10. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
11. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Today, iHealth Lab Inc. announced it has ... for its first institutional round of funding. The strategic ... reach, accelerate growth and innovation, and invest in additional ... Xiaomi Ventures will join iHealth,s board of directors, bringing ... ecommerce. "We are very pleased to have ...
(Date:9/19/2014)... DALLAS , September 19, 2014 ... Equipment Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), ... End Users (Hospitals), Advanced technologies - Global Forecast ... Market is poised to reach $19,786.3 Million by ... CAGR of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 The ... that Drive Medical Design and Manufacturing has joined the ... its CEO Harvey Diamond have been actively ... year history, as it has quickly grown into a ... corporate partners like Drive allows AAHomecare to increase efforts ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Young Innovations, Inc. (Nasdaq: YDNT ) today announced that it will broadcast ... call on Wednesday, July 21, 2010 at 11:00 a.m. Central ... InterCall at http://tinyurl.com/yiq210 . Access to the live audio broadcast will also ... , , ...
... Ill. , July 14 RoundTable Healthcare ... the health-care industry, announced today that it has entered ... portfolio companies, Bioniche Pharma Holdings Limited ("Bioniche Pharma") to ... pharmaceutical company, for $550 million in cash. ...
Cached Medicine Technology:Young Innovations, Inc. Provides 2nd Quarter Conference Call Details 2RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc. 2RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc. 3
(Date:9/22/2014)... 22, 2014 Back pain is a daily ... idea of instant powerful pain relief without taking a dangerous ... in technology have made this very possible. Enter on-line retailer ... iReliev Tens Unit electronic back massager. This ... back pain relief each and every day, in a ...
(Date:9/22/2014)... California (PRWEB) September 22, 2014 Plugin ... of ProSparkle. A fully customizable 3D particle emitter made ... “Adding the ProSparkle particle emitter plugin to a video ... Christina Austin, CEO of Pixel Film Studios. “ProSparkle gives ... described as cool” , With ProSparkle users are given ...
(Date:9/22/2014)... Cleveland, Ohio (PRWEB) September 22, 2014 ... to announce its recognition by ERC as ... award honors Northeast Ohio’s best places to work for ... their ability to build and maintain great workplaces that ... Areas which are evaluated include staffing and workforce, development ...
(Date:9/22/2014)... A Case Management Order (CMO) was issued on ... for testosterone lawsuit claims pending in multidistrict litigation in ... Wright & Schulte LLC notes the CMO, parties ... about potential witnesses and documents in testosterone therapy lawsuits. ... topics in Plaintiff Fact Sheets before another status conference ...
(Date:9/22/2014)... September 22, 2014 Reflecting their position ... iron products, Strictly Doors and Gates is now ... reasonable prices. The company offers quality wrought iron ornamental ... They have a versatile range of ornamental doors that ... will also get custom-made ornamental doors wherein their specifications ...
Breaking Medicine News(10 mins):Health News:Online Retailer Variety4Kicks Announces An Over The Counter Tens Unit For Back Pain Relief Is Now Available For Sale 2Health News:Announcing a new ProSparkle Particle Emitter Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 3Health News:Judge Issues CMO For Testosterone Lawsuits Alleging Heart Attacks and Strokes Caused By "Low T" Drugs Such As Androgel 2Health News:Judge Issues CMO For Testosterone Lawsuits Alleging Heart Attacks and Strokes Caused By "Low T" Drugs Such As Androgel 3Health News:Judge Issues CMO For Testosterone Lawsuits Alleging Heart Attacks and Strokes Caused By "Low T" Drugs Such As Androgel 4Health News:Judge Issues CMO For Testosterone Lawsuits Alleging Heart Attacks and Strokes Caused By "Low T" Drugs Such As Androgel 5Health News:Strictly Doors and Gates Now Adding Ornamental Iron Gates to Their Products Line 2
... 6, GlaxoSmithKline (NYSE: GSK ) announced today ... Inc. (Sirtris),for approximately USD720 million (or approx. GBP362 ... USD22.50 (or approx. GBP11.33) per share., Through ... its,metabolic, neurology, immunology and inflammation research efforts by,establishing ...
... led by Professor Makoto Tominaga and Research Assistant Professor ... found that a sour taste receptor, PKD1L3-PKD2L1 channel complex, ... only after the removal of acid stimulus. They call ... taste receptor. They reports their finding in an international ...
... HOUSTON, June 6 Carriage Services, Inc.,(NYSE: ... its "Company & Investment,Profile", which can be found ... updated Company & Investment Profile includes updated,discussions of ... financial outlook and more., The Company & ...
... TreAura, Reminder Service, Edge Health Solutions brings Medicine 2.0 to ... ... RICHMOND, British Columbia, June 5 Edge Health,Solutions, innovators of medical ... Mac OS X, announces the,release of edgeMD 2.0(TM) and edgeDMS 2.0(TM). ...
... CHICAGO, June 5 In a June 5 joint ... America (ELCA) and,the Episcopal Church urged U.S. citizens to ... action" from the international community to restore,stability there., ... the Rev. Katharine Jefferts,Schori of the Episcopal Church made ...
... nearly halved in Dutch study , , THURSDAY, June 5 (HealthDay ... treatment of a heart attack reduced the one-year death rate ... cardiologists said could change medical practice. , The latest data ... that just 19 of 535 heart attack victims -- 3.6 ...
Cached Medicine News:Health News:Carriage Services Updates Company & Investment Profile 2Health News:Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization 2Health News:Lutheran, Episcopal Church Presiding Bishops Urge Prayers for Peace in Sudan 2Health News:Sucking Out Clot Debris Helps Heart Attack Patients 2Health News:Sucking Out Clot Debris Helps Heart Attack Patients 3
... enzyme immunoassay kit for the quantitative ... in serum. Enzyme immunoassay (EIA) permits ... protein hormones in body fluids and ... and specific assay. This enzyme immunoassay ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... The determination of Ang II ... monitoring the pharmacological effect and ... of angiotensin converting enzyme inhibitors ... receptor antagonists as well as ...
Medicine Products: